Ibogaine Cardiac Safety — What Every Practitioner Must Know

QT Prolongation

Ibogaine prolongs the QT interval on EKG — the time between ventricular depolarization and repolarization. Excessive QT prolongation can lead to Torsades de Pointes, a potentially fatal ventricular arrhythmia.

Bradycardia

Ibogaine commonly causes bradycardia (slowed heart rate) during the acute phase. Heart rates of 40–50 bpm are common and generally well-tolerated in healthy patients, but require monitoring.

Mandatory Cardiac Monitoring

Continuous cardiac monitoring (pulse oximetry minimum, cardiac monitor preferred) is required throughout the ibogaine session and for at least 24 hours post-dose. QTc must be measured before dosing.

Emergency Response Readiness

Clinical settings must have crash cart access, trained staff capable of managing cardiac emergencies, and a clear protocol for transferring patients to emergency medical care if needed.

The Cardiac Pharmacology of Ibogaine

Ibogaine affects the heart through multiple mechanisms. It blocks hERG potassium channels, which are responsible for cardiac repolarization — this is the primary mechanism of QT prolongation. It also has sodium channel blocking activity, which contributes to its antiarrhythmic effects at low doses but can cause arrhythmias at higher doses. Its effects on the autonomic nervous system contribute to bradycardia.

The cardiac effects of ibogaine are dose-dependent and time-dependent. QT prolongation is most pronounced during the first 8–12 hours after administration and gradually resolves over 24–48 hours. Bradycardia typically peaks in the first 4–8 hours and resolves within 24 hours.

Monitoring Protocol

Before dosing: 12-lead EKG with QTc measurement. QTc must be below 450ms (men) or 470ms (women) to proceed. Electrolytes (potassium, magnesium) must be within normal range — hypokalemia and hypomagnesemia increase arrhythmia risk and must be corrected before treatment.

During the session: Continuous pulse oximetry is the minimum requirement. Continuous cardiac monitoring (telemetry or bedside monitor) is strongly preferred. Vital signs should be recorded every 30–60 minutes during the acute phase. A physician or trained clinical facilitator must be present or immediately available throughout the session.

How many ibogaine deaths have been cardiac-related?

The majority of documented ibogaine-related deaths have involved cardiac causes — primarily ventricular arrhythmias. Most of these deaths occurred in settings without adequate screening (undetected cardiac conditions) or without monitoring. In properly screened and monitored clinical settings, the cardiac safety record is significantly better.

What is the safe QTc threshold for ibogaine?

Most clinical protocols use QTc <450ms (men) or <470ms (women) as the threshold for proceeding with ibogaine treatment. Some protocols use more conservative thresholds of <440ms. Any QTc above the threshold is an absolute contraindication.

What medications increase cardiac risk with ibogaine?

Many medications prolong the QT interval and significantly increase cardiac risk when combined with ibogaine. These include: antipsychotics (haloperidol, quetiapine), certain antibiotics (azithromycin, fluoroquinolones), antifungals (fluconazole), antihistamines (diphenhydramine), and methadone. A complete medication review is essential before treatment.

Is ibogaine cardiac risk higher for older patients?

Yes. Age-related cardiac changes, higher rates of underlying cardiac disease, and more complex medication regimens make older patients higher risk for ibogaine cardiac adverse events. More conservative dosing and enhanced monitoring are appropriate for patients over 50.